- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
AML | Clinical
Ivosidenib Plus Azacitidine Improves Survival and Responses in IDH1-Mutated AML
September 29, 2022
Results from the phase 3 AGILE study presented at SOHO 2022 show that ivosidenib plus azacitidine prolong event-free and overall survival with good responses vs placebo in patients with IDH1-mutated acute myeloid leukemia
The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)
September 29, 2022
Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.
An Overview of Myelodysplastic Syndrome (MDS)
September 29, 2022
Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.
FLT3 Mutated AML: Are Triplets Better Than Doublets?
September 28, 2022
FLT3 tyrosine kinase inhibitor combination regimens may hold promise to not only improve outcomes for older individuals with FLT3-mutant but potentially for all patients , regardless of age or fitness.
Research Looks to Improve Outcomes in TP53-Mutant AML and MDS
September 26, 2022
Melhem Solh, MD, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.
Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML
August 31, 2022
In an interview with Targeted Oncology, Eunice S. Wang, MD, discussed the growing use of menin inhibitors in acute myeloid leukemia, and clinical trial research further supporting the treatment strategy.
FDA Lifts Partial Clinical Hold on the TakeAim Leukemia Study of Emavusertib
August 30, 2022
The FDA has cleared TakeAim Leukemia study to continue enrolling emavusertib with or without azacytidine and venetoclax in patients with acute myeloid leukemia or myelodysplastic syndrome.
FDA Places Full Clinical Hold on Study of FHD-286 in R/R AML and MDS
August 24, 2022
Due to suspected cases of fatal differentiation syndrome in a clinical trial, the FDA has placed a full clinical hold on the study of FHD-286 in acute myeloid leukemia and myelodysplastic syndrome.
Study of Lanraplenib and Gilteritinib Doses First Patient With FLT3+ AML
August 24, 2022
A phase 1b/2 clinical trial aims to evaluate the safety of lanraplenib plus gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
OS Improves With Quizartinib Plus Chemo in Newly Diagnosed FLT3 ITD+ AML
August 19, 2022
According to results from the QuANTUM-First, quizartinib significantly improved overall survival vs standard of care in patients with newly diagnosed FLT3 ITD–positive acute myeloid leukemia.